This past week has been dynamic for clinical research, marked by significant regulatory advancements, substantial biopharmaceutical investments, and innovative technological developments. These updates highlight a field rapidly evolving to accelerate drug development, enhance data accessibility, and improve patient outcomes through cutting-edge approaches.
Key Clinical Research News & Trends
-
FDA Grants Orphan Drug Designation to Rilzabrutinib for Sickle Cell Disease
On June 3, 2025, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to rilzabrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor. This significant designation is for the treatment of sickle cell disease, a rare and debilitating condition affecting fewer than 200,000 people in the U.S.. Rilzabrutinib is designed to reduce vaso-occlusive crises, which are a hallmark of the disease, by targeting inflammation. This marks the fourth orphan drug designation for rilzabrutinib in rare diseases, underscoring its potential across multiple underserved patient populations.
Published: June 3, 2025
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease -
NIH Public Access Policy Undergoes Major Changes Effective July 1, 2025
On June 3, 2025, news emerged about significant changes to the NIH Public Access Policy, effective July 1, 2025. This updated policy mandates that all peer-reviewed journal articles resulting from NIH-funded research must be deposited into PubMed Central (PMC) and made immediately publicly available upon publication. Crucially, previous embargo periods, which allowed publishers exclusive access for a period, will no longer be permitted. This shift aims to enhance the accessibility of research findings but requires researchers to adapt their publication workflows to ensure compliance, with potential consequences for non-adherence.
Published: June 3, 2025
Important Changes to NIH Public Access Policy Effective July 1, 2025 - Medicine in Motion News -
FDA Lifts Partial Clinical Hold on IFx-2.0 Phase 3 Trial for Merkel Cell Carcinoma
On June 9, 2025, the FDA lifted a manufacturing-related partial clinical hold on TuHURA Biosciences’ pivotal Phase 3 accelerated approval trial of IFx-2.0. This investigational intralesional innate immune agonist is being evaluated as an adjunctive therapy to pembrolizumab for the first-line treatment of advanced or metastatic Merkel cell carcinoma (MCC), a rare but aggressive skin cancer. The regulatory action allows TuHURA Biosciences to proceed with initiating and activating clinical sites for the pivotal study. IFx-2.0 aims to overcome primary resistance to checkpoint inhibitors by “priming” the immune system.
Published: June 9, 2025
FDA Lifts Partial Clinical Hold on IFx-2.0 Phase 3 Trial for Merkel Cell Carcinoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways -
Biopharma Sector Sees Significant Funding and Strategic Partnerships
The week of June 3-9, 2025, witnessed substantial financial activity across the U.S. biopharmaceutical landscape, signaling robust investor confidence and continued innovation. Notable funding rounds included SpyGlass Pharma securing $75 million in Series D funding to advance its Drug Delivery Platform through two Phase III pivotal trials for long-term glaucoma management. Allay Therapeutics raised $57.5 million in Series D for a Phase 2b registration trial targeting post-surgical pain. Additionally, Trevi Therapeutics raised $100 million in post-IPO equity for chronic cough therapies. These significant investments, alongside strategic partnerships like the ~$11.1 billion global co-development deal between BioNTech and Bristol Myers Squibb for a bispecific antibody in solid tumors, underscore a vibrant ecosystem.
Published: June 9, 2025
BioPharma Updates 9th June, 2025 | SciLeads
Tools & Tips
- Datavant Connect: Accelerating Real-World Data Analysis with Privacy Datavant Connect, built on AWS Clean Rooms, is a groundbreaking new platform designed to revolutionize real-world data (RWD) analysis for clinical researchers. It enables the secure analysis of linked patient data without exposing protected health information (PHI), drastically reducing the traditional data discovery process from four months to just two weeks. This tool maintains data owner control and includes built-in Health Insurance Portability and Accountability Act (HIPAA) compliance and governance features, ensuring that privacy is not compromised for speed.
Highlights from the 2025 AWS Life Sciences Symposium’s Clinical Trials track | AWS for Industries
Fun Fact
Did you know that despite common misconceptions, placebos are rarely used in cancer clinical trials? It is considered unethical to give a placebo when an effective treatment is available. Placebos are primarily reserved for situations where no standard treatment exists, or to compare an experimental treatment plus standard care against standard care plus a placebo. This ethical guideline underscores the rigorous patient safety and welfare standards that govern modern clinical research.
Facts About Clinical Trials - NCI
We’d love to hear from you!
Have you participated in any Clinical Research events or utilized new Clinical Research tools recently? Share your experiences or insights with us—we’re featuring selected community voices in next week’s edition.